6086-24-4

Basic information

• Product Name: BENZOFUROXAN-5-CARBOXYLIC ACID
• Synonyms: 5-CARBOXY-2,1,3-BENZOXADIAZOL-1-IUM-1-OLATE;AKOS BB-7018;BENZOFUROXAN-5-CARBOXYLIC ACID;BUTTPARK 88\04-07;5-CARBOXYBENZOFURAZAN-1-OXIDE;2,1,3-Benzoxadiazole-5-carboxylic acid N-oxide
• CAS NO: 6086-24-4
• Molecular Formula: C₇H₄N₂O₄
• Molecular Weight: 180.12
• EINECS: 926-284-4
• Mol File: 6086-24-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 125-131°C
• Boiling Point: 631.2°C at 760 mmHg
• Flash Point: 335.5°C
• Appearance: /
• Density: 1.37g/cm³
• Vapor Pressure: 7.67E-16mmHg at 25°C
• Refractive Index: 1.641
• PKA: 1.97±0.30(Predicted)
• BRN: 612513
• CAS DataBase Reference: BENZOFUROXAN-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOFUROXAN-5-CARBOXYLIC ACID(6086-24-4)
• EPA Substance Registry System: BENZOFUROXAN-5-CARBOXYLIC ACID(6086-24-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 6086-24-4(Hazardous Substances Data)

Usage

General Description

Benzofuroxan-5-carboxylic acid, also designated as 1,2,5-Oxadiazole 4-oxide 2-furanecarboxylic acid, is a chemical compound of the benzofuroxan family. Its chemical formula is C5H2N2O5 and its molecular weight is 172.08 g/mol. It is often used in chemical research and synthesis given its properties. Specific details about its stability, toxicity, or typical reactions are currently not well-documented in the literature, requiring careful handling and used only by trained professionals for specific applications. It is recommended to store it in a cool, dry place, away from strong oxidizing agents.

InChI:InChI=1/C16H24N4O2S3/c21-13(19-7-3-1-4-8-19)11-23-15-17-16(25-18-15)24-12-14(22)20-9-5-2-6-10-20/h1-12H2

Upstream product

• 54974-60-6 4-azido-3-nitro-benzoic acid 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 39608-47-4 3-chloro-4-nitrobenzoic acid 
• 1588-83-6 4-amino-3-nitrobenzoic acid 

Downstream Products

• 36389-06-7 5-acetylbenzofuroxan 
• 6086-26-6 1-oxy-benzo[1,2,5]oxadiazole-5-carbonyl chloride 
• 19155-88-5 benzo[c][1,2,5]oxadiazole-5-carboxylic acid 
• 54286-62-3 benzo[c][1,2,5]oxadiazole-5-carbonitrile 
• 126147-86-2 benzofurazan-5-carbonyl chloride 
• 1061063-13-5 N-[1-(3,5-dimethylphenyl)-1H-4,5,6,7-tetrahydroindazol-4-yl]-2,1,3-benzoxadiazole-5-carboxamide 1-oxide 

Relevant articles and documents

BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning, hi a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity

A novel series of histone deacetylases inhibitors (HDACIs) containing benzofuroxan pharmacophore as nitric oxide (NO) donor were designed based on the combination principle and 'multifunctional drugs' theory. As a novel study on embedding NO donor into th